单位：[1]Department of Hematology, Chinese PLA General Hospital, Beijing, China[2]Department of Hematology, Fujian Institute of Hematology, Fuzhou, China[3]Department of Hematology, The Forth Medical Center of PLA General Hospital, Beijing, China[4]Center of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China[5]Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[6]Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China临床科室血液科血液科首都医科大学附属北京友谊医院[7]Department of Hematology, Peking University First Hospital, Beijing, China[8]Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, China
The number of HLA-haploidentical allogeneic hematopoietic stem-cell transplantation (Haplo-HSCT) is increasing. Comparative studies about Haplo-HSCT versus allo-HSCT with HLA-matched sibling donors (MSD-HSCT) have been tried in leukemias and B-cell lymphomas. Few studies were reported in Peripheral T-cell lymphomas (PTCLs). We performed a multicenter retrospective study about 52 patients with PTCLs undergoing Haplo-HSCT (n = 20) or MSD-HSCT (n = 32). All Haplo-HSCT recipients received antithymocyte globulin (ATG) based graft versus host disease (GVHD) prophylaxis. The median follow-up for all survivors was 38 months. The 100-day cumulative incidence of grade II to IV acute GVHD was similar (19% in the MSD-HSCT group versus 28% in the Haplo-HSCT group, P = 0.52). The 2-year cumulative incidence of chronic GVHD (limited and extensive) after Haplo-HSCT (30%) was also similar with that in the MSD-HSCT group (50%, P = 0.15). The 3-year relapse rates (33% vs 27%, P = 0.84) and non-relapse mortality (21% vs 22%, P = 0.78) did not differ between these two groups. There were also no differences in 3-year overall survival (OS) (48% vs 50%, P = 0.78) and progression-free survival (47% vs 51%, P = 0.95) between these two groups. On multivariate analysis, prognostic index for T-cell lymphoma (PIT) score (higher than 1: hazard ratio [HR], 4.0; P = 0.003) and disease status (stable or progression disease before HSCT: HR, 2.8; P = 0.03) were independent variables associated with worse OS. We concluded that ATG-based haplo-HSCT platform could work as an alternative to MSD-HSCT for patients with PTCLs.
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|3 区医学
小类|3 区医学：研究与实验3 区移植4 区细胞与组织工程
最新[2025]版：
大类|4 区医学
小类|3 区移植4 区细胞与组织工程4 区医学：研究与实验
JCR分区：
出版当年[2019]版：
Q2TRANSPLANTATIONQ2MEDICINE, RESEARCH & EXPERIMENTALQ3CELL & TISSUE ENGINEERING
最新[2023]版：
Q2MEDICINE, RESEARCH & EXPERIMENTALQ2TRANSPLANTATIONQ3CELL & TISSUE ENGINEERING
第一作者单位：[1]Department of Hematology, Chinese PLA General Hospital, Beijing, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Hematology, Chinese PLA General Hospital, Beijing, China[7]Department of Hematology, Peking University First Hospital, Beijing, China[8]Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, China[*1]Department of Hematology, Peking University First Hospital, Beijing 100034, China.[*2]Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing 100048, China.[*3]Department of Hematology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
推荐引用方式(GB/T 7714)：
Gu Zhenyang,Li Nainong,Wu Xiaoxiong,et al.Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas[J].CELL TRANSPLANTATION.2021,30:doi:10.1177/0963689721999615.
APA：
Gu Zhenyang,Li Nainong,Wu Xiaoxiong,Wang Maihong,Fu Xiaorui...&Huang Wenrong.(2021).Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas.CELL TRANSPLANTATION,30,
MLA：
Gu Zhenyang,et al."Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas".CELL TRANSPLANTATION 30.(2021)
